Omni Bio Pharmaceutical Appoints Dr. Michael Kamarck as New Director

Omni Bio Pharmaceutical Appoints Dr. Michael Kamarck as New Director 
DENVER, CO -- (Marketwire) -- 02/06/13 --  Omni Bio Pharmaceutical,
Inc. ("Omni Bio") (OTCBB: OMBP), a biopharmaceutical company focused
on the commercialization of alternative uses of alpha-1 antitrypsin
(AAT) for the treatment of a variety of indications and the
development of next-generation recombinant forms of AAT, today
announced the appointment of Michael E. Kamarck, Ph.D., to its Board
of Directors, effective January 31, 2013.  
From 2010 to 2012, Dr. Kamarck was employed by Merck as President of
Merck BioVentures and Senior Vice President of Vaccines and Biologics
Manufacturing. From 2001 to 2009, he was employed by Wyeth, where he
held various senior executive positions, including President,
Technical Operations and Product Supply and was responsible for
global technical operations for all of the Wyeth businesses. Dr.
Kamarck also served as a member of the Wyeth Management Committee.
Prior to Wyeth, he was employed by Bayer AG for 17 years in a variety
of technical and leadership capacities. Dr. Kamarck received his B.A.
from Oberlin College, his Ph.D. from MIT and was a Leukemia Society
Fellow at Yale University. 
Dr. Bruce E. Schneider, CEO of Omni Bio, commented, "We are extremely
pleased and very fortunate to have Dr. Kamarck join Omni Bio. His
proven track record in developing and manufacturing complex
biologicals, along with his highly-regarded stature in the
biopharmaceutical community, will be enormously valuable to us as we
embark on next steps in the development of recombinant AAT." 
About Omni Bio Pharmaceutical, Inc. 
Omni Bio Pharmaceutical (www.omnibiopharma.com) is a
biopharmaceutical company that is focused on AAT and on developing
new recombinant versions of AAT that can be applied to the treatment
of a broad range of indications including, for example, Type 1
diabetes, graft rejection, graft versus host disease (GVHD), cardiac
conditions and inflammatory bowel diseases. Since its formation, Omni
Bio has supported research using animal models and human clinical
studies that demonstrate that AAT is a promising agent for
ameliorating these conditions. 
Forward-Looking Statements
 Some of the statements made in this press
release are forward-looking state
ments that reflect management's
current views and expectations with respect to future events. These
forward-looking statements are not a guarantee of future events and
are subject to a number of risks and uncertainties, many of which are
outside our control, which could cause actual events to differ
materially from those expressed or implied by the statements. These
risks and uncertainties are based on a number of factors, including
but not limited to the business risks disclosed in our SEC filings,
especially the section entitled "Risk Factors" in our Annual Report
on Form 10-K for the fiscal year ended March 31, 2012. We undertake
no obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events or
otherwise. 
Omni Bio Pharmaceutical, Inc.
Bob Ogden 
Chief Financial Officer - Investor Relations
(720) 488-4754   
Email - investor_relations@omnibiopharma.com 
 
 
Press spacebar to pause and continue. Press esc to stop.